Clinical efficacy and safety of rimegepant in the treatment of migraine: a meta-analysis of randomized controlled trials [PDF]
Frontiers in Neurology, 2023 BackgroundThis study aims to evaluate the clinical efficacy and safety of rimegepant for the treatment of migraine in adult patients using a meta-analysis.MethodsThe PubMed, EMBASE, and Cochrane Library were searched up to March 2022.
Qinghui Wang +3 more
doaj +3 more sources
Gepants: targeting the CGRP pathway for migraine relief [PDF]
Frontiers in PharmacologyBackgroundCalcitonin gene–related peptide (CGRP) receptor antagonist (collectively known as gepant) have emerged as effective therapies for both acute migraine treatment and preventive management.
Bernadetta Jakubowska +2 more
doaj +2 more sources
Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine
New England Journal of Medicine, 2019 Calcitonin gene-related peptide receptor has been implicated in the pathogenesis of migraine. Rimegepant is an orally administered, small-molecule, calcitonin gene-related peptide receptor antagonist that may be effective in acute migraine treatment.In a multicenter, double-blind, phase 3 trial, we randomly assigned adults with at least a 1-year ...
Gene M Dubowchik, Peter Goadsby
exaly +4 more sources
Post-marketing safety concerns with rimegepant based on a pharmacovigilance study
The Journal of Headache and PainPurpose This study aimed to comprehensively assess the safety of rimegepant administration in real-world clinical settings. Methods Data from the Food and Drug Administration Adverse Event Reporting System (FAERS) spanning the second quarter of 2020 ...
Jia-Ling Hu +5 more
doaj +3 more sources
Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
CNS Drugs, 2023 Rimegepant [Nurtec® ODT (USA); Vydura® (EU)] is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine with or without aura in adults, and for the preventive treatment of episodic migraine in adults.
exaly +3 more sources
Retrospective analysis of the tolerability and effectiveness of rimegepant for the acute treatment of migraine in adolescents. [PDF]
HeadacheAbstract Objective This study aims to evaluate the tolerability and effectiveness of the off‐label use of rimegepant as acute migraine treatment in adolescents. Background Calcitonin gene‐related peptide (CGRP) levels are elevated during migraine attacks.
Tourlas K +4 more
europepmc +2 more sources
Integrating gepants into clinical practice for the acute treatment of migraine. [PDF]
HeadacheAbstract Objective To assess the role of small‐molecule calcitonin gene–related peptide receptor antagonists (gepants) in the acute treatment of migraine, particularly in relation to triptan treatments. Background Triptans have established efficacy and are widely prescribed for the acute treatment of migraine.
Lipton RB +4 more
europepmc +2 more sources
Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo-controlled clinical trials. [PDF]
HeadacheAbstract Objective This post hoc subgroup analysis was conducted using pooled data from three US‐based clinical trials to compare efficacy and safety of rimegepant 75 mg versus placebo in acute migraine in adults who are Black or African American.
Charleston L +6 more
europepmc +2 more sources
A Phase 1, Randomized, Placebo-Controlled, Multiple-Dose, Double-Blind Study to Evaluate and Compare the Pharmacokinetics and Safety of Rimegepant in Healthy Adult Japanese and Caucasian Individuals. [PDF]
Clin Pharmacol Drug DevAbstract This Phase 1, randomized, placebo‐controlled, double‐blind study assessed the pharmacokinetic profile of rimegepant (25, 75, or 150 mg once daily for 14 days) in healthy Japanese and Caucasian adults. Exposures were modestly increased in Japanese participants compared with Caucasian participants following a single dose of rimegepant (Day 1 ...
Bhardwaj R +6 more
europepmc +2 more sources
Blocking the CGRP Receptor:Differences across Human Vascular Beds [PDF]
, 2023 Multiple drugs targeting the calcitonin gene-related peptide (CGRP) receptor have been developed for the treatment of migraine. Here, the effect of the small-molecule CGRP receptor antagonist zavegepant (0.1 nM–1 µM) on CGRP-induced relaxation in ...
Boucherie, Deirdre M. +4 more
core +2 more sources